HALOZYME THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
HALOZYME THERAPEUTICS, INC. (HALO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $2.49 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-02-21
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-12-31 was $10.81M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-09-30 was $35.19M, a 16.21% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-06-30 was -$7.61M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$35.90M, a 941.74% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was $2.49M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$163.73M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$76.77M, a 1403.77% decline from fiscal 2015.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $5.89M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-12-31 | $10.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $46.00M derived: sum of 2 quarters · filed 2019-02-21 | $38.39M derived: sum of 3 quarters · filed 2019-02-21 | $2.49M 10-K · filed 2019-02-21 |
| 2018-09-30 | $35.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $27.58M derived: sum of 2 quarters · filed 2018-11-06 | -$8.32M 10-Q · filed 2018-11-06 | -$157.30M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-06-30 | -$7.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$43.51M 10-Q · filed 2018-08-07 | -$192.50M derived: sum of 3 quarters · filed 2019-02-21 | -$162.21M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-03-31 | -$35.90M 10-Q · filed 2018-05-10 | -$184.89M derived: sum of 2 quarters · filed 2019-02-21 | -$154.60M derived: sum of 3 quarters · filed 2019-02-21 | -$203.90M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-12-31 | -$148.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$118.70M derived: sum of 2 quarters · filed 2019-02-21 | -$168.00M derived: sum of 3 quarters · filed 2019-02-21 | -$163.73M 10-K · filed 2019-02-21 |
| 2017-09-30 | $30.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$19.01M derived: sum of 2 quarters · filed 2018-11-06 | -$14.74M 10-Q · filed 2018-11-06 | $6.30M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-06-30 | -$49.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$45.03M 10-Q · filed 2018-08-07 | -$23.98M derived: sum of 3 quarters · filed 2019-02-21 | -$15.74M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-03-31 | $4.26M 10-Q · filed 2018-05-10 | $25.31M derived: sum of 2 quarters · filed 2019-02-21 | $33.56M derived: sum of 3 quarters · filed 2019-02-21 | $33.12M derived: sum of 4 quarters · filed 2019-02-21 |
| 2016-12-31 | $21.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $29.29M derived: sum of 2 quarters · filed 2019-02-21 | $28.86M derived: sum of 3 quarters · filed 2019-02-21 | -$76.77M 10-K · filed 2019-02-21 |
| 2016-09-30 | $8.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $7.81M derived: sum of 2 quarters · filed 2017-11-07 | -$97.81M 10-Q · filed 2017-11-07 | -$112.57M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | -$435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$106.06M 10-Q · filed 2017-08-08 | -$120.81M derived: sum of 3 quarters · filed 2018-02-20 | -$100.52M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | -$105.62M 10-Q · filed 2017-05-09 | -$120.38M derived: sum of 2 quarters · filed 2018-02-20 | -$100.08M derived: sum of 3 quarters · filed 2018-02-20 | -$89.31M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | -$14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $5.54M derived: sum of 2 quarters · filed 2018-02-20 | $16.31M derived: sum of 3 quarters · filed 2018-02-20 | $5.89M 10-K · filed 2018-02-20 |
| 2015-09-30 | $20.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $31.06M derived: sum of 2 quarters · filed 2016-11-07 | $20.64M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $10.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $351.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$10.42M 10-Q · filed 2016-05-09 | |||
| 2014-09-30 | -$46.43M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |